Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Northpond Ventures

Investor type Venture Capital
Founders Michael Rubin Sharon Kedar

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 102
Average round size
info
The average size of a deal this fund participated in
$40M
Portfolio companies 67
Rounds per year 25.50
Lead investments 23
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.34
Exits 2
Key employees 3
Stages of investment
Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Health Diagnostics
  • Medical
  • Life Science
Summary

In 2018 was created Northpond Ventures, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Bethesda.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Northpond Ventures, startups are often financed by ARCH Venture Partners, Sands Capital Ventures, Connecticut Innovations. The meaningful sponsors for the fund in investment in the same round are Sands Capital Ventures, Think.Health, Spring Mountain Capital. In the next rounds fund is usually obtained by National Cancer Institute SBIR Development Center, Think.Health, Spring Mountain Capital.

The real fund results show that this VC is 64 percentage points more often commits exit comparing to other companies. The fund is generally included in 13-24 deals every year. The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund.

The current fund was established by Michael Rubin, Sharon Kedar. Besides them, we counted 3 critical employees of this fund in our database.

Among the various public portfolio startups of the fund, we may underline Ultivue, 908 Devices, Candel Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical, Software. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Northpond Ventures:
Typical Co-investors
Northpond Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Northpond Ventures:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Opna Bio

Health Care
Therapeutics
$38M21 Nov 2022 Epalinges, Vaud, Switzerland

EnPlusOne Biosciences

Biotechnology
Therapeutics
$12M30 Sep 2022 Watertown, Massachusetts, United States

Elephas Biosciences

Health Care
Medical
Medical Device
$41M06 Sep 2022 Madison, Wisconsin, United States

Vestaron

Agriculture
Biotechnology
Farming
$10M25 Aug 2022 Durham, North Carolina, United States

Syapse

Big Data
Bioinformatics
Cloud Computing
Health Care
Information Services
Information Technology
SaaS
$35M27 Jul 2022 San Francisco, California, United States

CAMP4 Therapeutics

Biopharma
Biotechnology
Therapeutics
$100M20 Jul 2022 Cambridge, Massachusetts, United States

Molecule

Blockchain
Health Care
Life Science
Software
$13M15 Jun 2022 Berlin, Berlin, Germany

Code Biotherapeutics

Biotechnology
Life Science
$75M07 Jun 2022 Hatfield, Pennsylvania, United States

Vizgen

Biotechnology
$85M03 Jun 2022 Cambridge, Massachusetts, United States
News
SimBioSys Raises $15 Million Series A to Develop the Future of Precision Cancer Care

– SimBioSys announced it raised $15m in Series A funding to accelerate the development and commercialization of its TumorScope software platform.
– The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients.
– This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic.
– Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21m.
– In the first half of 2021, SimBioSys tripled its headcount, bringing in expert clinicians, scientists, and executives from the life sciences industry.

Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama

– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Northpond Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: